Xiaomi is reportedly working on a wide-screen slab phone

Xiaomi is reportedly developing a wide-screen slab phone, similar to the cover screens on wide foldables like the Galaxy Z Fold 8 and iPhone Duo. The device may feature a side-mounted fingerprint scanner, according to leaker Digital Chat Station.

Original reporting
Published Nov 4, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Xiaomi is reportedly working on a wide-screen slab phone — source image
Decision brief

The 30-second read

Low
01

Why it matters

The announcement is speculative and may generate short‑term curiosity but unlikely to move the stock significantly.

02

Market read

A product rumor with modest relevance; limited trading action expected.

03

What to watch

Supply chain constraints and competition from foldable devices could hinder adoption.

Relevance 4/10Novelty 3/10Timing: immediate

Background

Xiaomi has been expanding its smartphone portfolio; wide‑screen designs are emerging as a niche.

Market effects

May signal broader interest in wide‑screen slab phones, affecting other Chinese smartphone makers.

Limited to Chinese consumer electronics market.

Low global impact unless the product reaches international markets.

Counterpoint

The rumor could be hype; Xiaomi may delay or cancel the project, limiting any price effect.

Key entities

  • Xiaomi Corp.

    Chinese smartphone manufacturer, ticker VIE.

Related articles

$FLEXMed

India says Xiaomi, Flextronics hid royalty deals in tariff fight

India accuses Xiaomi and Flex of hiding royalty deals in a tax dispute. The government claims Xiaomi's India unit failed to fully disclose royalty agreements, potentially costing it over $150 million. The case is seen as a test for India's stance on contract manufacturing. Both Xiaomi and Flex have challenged the tax tribunal's rulings, but the government seeks to dismiss these challenges.

$1810.HKHigh

Why is Xiaomi stock surging today?

Xiaomi stock rose 6.3% to HK$28.14 after its EV division reported October deliveries exceeding 50,000 units, its best monthly performance in 2026. Citi reiterated its 'Buy' rating with a HK$33.2 target, citing delivery data and attractive valuation. The Hong Kong market also saw gains, with the Hang Seng Tech Index up 2.85%.

$VNRXMed

VolitionRx reports clinical progress across diagnostic platform

VolitionRx (VNRX) reported progress in its Nu.Q diagnostic platform, with high sensitivity and specificity in detecting cancers. Its Nu.Q NETs test is part of a €6.3M French program. The company saw a 134% revenue increase, reduced operating losses, and is in licensing discussions. It also expanded a supply agreement with Fujifilm Vet Systems for a feline cancer test.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.